이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Neoadjuvant Trastuzumab Rezetecan Plus Toripalimab and Endocrine Therapy in HR-Positive HER2-Low Breast Cancer

An Exploratory Prospective Single-Arm Study of Trastuzumab Rezetecan Combined With Toripalimab and Endocrine Therapy as Neoadjuvant Treatment in Patients With Stage II-III HR-Positive, HER2-Low Primary Breast Cancer

This is a single-arm, prospective exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of trastuzumab rezetecan (SHR-A1811) combined with toripalimab and endocrine therapy as neoadjuvant treatment for patients with stage II-III HR-positive, HER2-low primary breast cancer.

Eligible participants will receive the combination neoadjuvant regimen before surgery. The primary endpoint is pathological complete response (pCR, ypT0/is ypN0) rate after surgery. Secondary endpoints include objective response rate (ORR), residual cancer burden (RCB), event-free survival (EFS), overall survival (OS), and safety.

A total of 30 participants will be enrolled. The recruitment period will last for 12 months. All enrolled subjects will receive study treatment and follow-up according to the study protocol.

연구 개요

연구 유형

중재적

등록 (추정된)

30

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Tianjin, 중국, 300060
        • 모병
        • Tianjin Medical University Cancer Institute and Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  1. Aged ≥18 and ≤70 years old.
  2. Histopathologically confirmed invasive breast cancer; no prior systemic anti-tumor therapy for breast cancer.
  3. Histopathologically confirmed HR-positive (ER >1%) and HER2-low breast cancer. HER2-low is defined as IHC 1+ or IHC 2+ with ISH-negative.
  4. Ki-67 proliferation index ≥30%.
  5. Stage II-III breast cancer per the 8th edition AJCC TNM staging criteria (cT2 N1-2 M0, or T3-4 N0-2 cM0).
  6. At least one measurable target lesion according to RECIST Version 1.1.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  8. Female participants may be pre-menopausal, peri-menopausal or post-menopausal. Post-menopause is defined according to CSCO Breast Cancer Guidelines as any one of the following:

Bilateral oophorectomy;

  1. Age ≥ 60 years;
  2. Age < 60 years with spontaneous amenorrhea for ≥12 months; no chemotherapy, tamoxifen, toremifene or ovarian function suppression in the past 12 months, and post-menopausal levels of FSH and estradiol;
  3. Age < 60 years receiving tamoxifen or toremifene, with post-menopausal FSH and estradiol levels documented on two consecutive tests.

9、Adequate organ function (no blood product or growth-factor-supported correction within 14 days prior to first study drug administration):

  1. Hematologic function: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelets ≥ 100 × 10⁹/L; hemoglobin ≥ 90 g/L.
  2. Hepatic and renal function: Albumin ≥ 3.0 g/dL; total bilirubin ≤ 1.5 × ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; alkaline phosphatase ≤ 2.5 × ULN; blood urea nitrogen and serum creatinine ≤ 1.5 × ULN OR creatinine clearance ≥ 60 mL/min (calculated by Cockcroft-Gault formula).
  3. Coagulation: Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
  4. Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50% assessed by echocardiogram (ECHO).
  5. Electrocardiogram: QTcF (Fridericia-corrected QT interval) ≤ 470 ms for female subjects.

10、For pre-menopausal women of child-bearing potential: serum pregnancy test negative within 7 days before initiation of study treatment; non-lactating. All enrolled female participants must use adequate barrier contraception throughout treatment and for 6 months after completion of study treatment.

11、Voluntarily agrees to participate, provides written informed consent, demonstrates good compliance and is willing to complete all study-related visits and procedures.

Exclusion Criteria:

  1. Breast cancer without histopathological confirmation.
  2. Bilateral breast cancer, inflammatory breast cancer or occult breast cancer.
  3. Prior anti-neoplastic therapy of any modality (chemotherapy, radiotherapy, targeted therapy, endocrine therapy, etc.). Definitive radiotherapy received within 4 weeks before first study drug dose, or palliative radiotherapy received within 2 weeks before first study drug dose.
  4. Concurrent receipt of any other anti-tumor therapy.
  5. History of other malignancies within the past 5 years, except for cured basal-cell skin carcinoma and carcinoma in situ of cervix.
  6. Participation in another investigational-drug clinical trial within 4 weeks prior to enrollment.
  7. Received immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes (>10 mg/day prednisone equivalent) within 2 weeks before first study drug administration; nasal or inhaled corticosteroids are permitted.
  8. Administration of live or attenuated vaccines within 4 weeks prior to first study drug dose.
  9. Major surgery unrelated to breast cancer within 4 weeks before first study drug dose, or incomplete recovery from such surgery.
  10. Active autoimmune disease, or history of autoimmune disease prone to relapse (including but not limited to autoimmune hepatitis, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism; hypothyroidism controlled solely by hormone-replacement therapy is allowed). Subjects with skin disorders not requiring systemic therapy (vitiligo, psoriasis, alopecia), insulin-controlled type 1 diabetes, or childhood-onset asthma fully resolved without adult-time intervention may be enrolled. Asthma requiring bronchodilator intervention is excluded.
  11. History of immunodeficiency, including HIV-positive status, other acquired or congenital immunodeficiency, or history of organ transplantation.
  12. Uncontrolled or clinically significant cardiovascular-cerebrovascular disease. Any of the following occurring within 6 months prior to first dose: NYHA class III-IV congestive heart failure, myocardial infarction, cerebral infarction (lacunar infarction excluded), pulmonary embolism, unstable angina; arrhythmias requiring treatment at screening; primary cardiomyopathy (dilated, hypertrophic, arrhythmogenic right-ventricular, restrictive or unclassified cardiomyopathy); clinically significant history of QTc prolongation; second-degree type-II or third-degree atrioventricular block; female QTcF > 470 ms; atrial fibrillation (EHRA grade ≥ 2b); uncontrolled hypertension judged by investigator to make subject ineligible.
  13. Known or suspected interstitial pneumonia; moderate-to-severe pulmonary disease impairing respiratory function within 3 months before first dose that may confound detection/management of drug-related pulmonary toxicity, including idiopathic pulmonary fibrosis, organizing pneumonia / bronchiolitis obliterans, pulmonary embolism, severe asthma, severe COPD, obstructive/restrictive lung disease; autoimmune / connective-tissue / inflammatory diseases with pulmonary involvement (e.g. rheumatoid arthritis, Sjögren syndrome, sarcoidosis); prior total pneumonectomy.
  14. Active hepatitis B (HBsAg-positive with HBV-DNA ≥ 500 IU/mL), hepatitis C (HCV-antibody-positive with HCV-RNA above upper limit of normal), liver cirrhosis; severe infection requiring antibiotics, antiviral or antifungal therapy.
  15. Known inherited or acquired bleeding or thrombotic diathesis (e.g. hemophilia, coagulopathy).
  16. Known hypersensitivity or contraindications to study drugs or their excipients.
  17. Pregnant or lactating women; women of child-bearing potential with positive baseline serum pregnancy test; women of child-bearing potential unwilling to use effective contraception throughout the study period.
  18. Concomitant medical conditions that, in the investigator's judgment, would endanger subject safety or prevent completion of the study (including but not limited to uncontrolled severe hypertension, severe diabetes, active infection).
  19. Documented history of neurological or psychiatric disorders including epilepsy or dementia; or any other condition rendering the subject unsuitable for the study in the investigator's opinion.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Trastuzumab Rezetecan plus Toripalimab and Endocrine Therapy Neoadjuvant Treatment

Patients receive 6 cycles of neoadjuvant trastuzumab rezetecan (4.8 mg/kg IV Q3W) plus toripalimab (240 mg IV Q3W) plus daily endocrine therapy (SERM/AI ± OFS; OFS for pre/perimenopausal women), followed by surgery.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Pathological Complete Response Rate (pCR, ypT0/isN0)
기간: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).

Percentage of patients achieving pathological complete response (pCR, defined as ypT0/isN0) in breast and axillary lymph nodes after neoadjuvant therapy, assessed by central pathology review after surgery

At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).

2차 결과 측정

결과 측정
측정값 설명
기간
Objective Response Rate (ORR)
기간: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).

Percentage of patients with confirmed objective response (CR or PR) assessed by investigator according to RECIST criteria.

At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
Residual Cancer Burden (RCB)
기간: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).

RCB class and continuous RCB score determined from surgical specimens after neoadjuvant treatment.

At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
Event-Free Survival (EFS)
기간: Up to 3 years after surgery

Time from enrollment to first occurrence of invasive breast cancer recurrence, distant metastasis, second primary malignancy, or death from any cause, whichever comes first.

Up to 3 years after surgery
Overall Survival (OS)
기간: Up to 5 years after surgery

Time from enrollment to death from any cause.

Up to 5 years after surgery
Safety
기간: From start of study treatment up to 30 days after last dose of study drugs

Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) graded per CTCAE.

From start of study treatment up to 30 days after last dose of study drugs

기타 결과 측정

결과 측정
측정값 설명
기간
Immune biomarkers (sTIL, PD-L1, etc.)
기간: Baseline and at surgery

Assessment of immune biomarkers including stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1 expression in baseline tumor samples and post-treatment surgical specimens.

Baseline and at surgery
Ki-67 expression
기간: Baseline and at surgery

Change in Ki-67 proliferation index between baseline biopsy and surgical specimens after neoadjuvant therapy.

Baseline and at surgery

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 1일

기본 완료 (추정된)

2028년 5월 31일

연구 완료 (추정된)

2029년 5월 31일

연구 등록 날짜

최초 제출

2026년 11월 10일

QC 기준을 충족하는 최초 제출

2026년 11월 17일

처음 게시됨 (실제)

2026년 11월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 17일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • E20261415

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다